Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, August 1998, p. 1973-1979, Vol. 42, No. 8
SmithKline Beecham Pharmaceuticals,
Received 31 October 1997/Returned for modification 9 February
1998/Accepted 31 May 1998
The
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
In Vitro Activities of Oral
-Lactams at Concentrations
Achieved in Humans against Penicillin-Susceptible and
-Resistant Pneumococci and Potential to Select Resistance
-lactam susceptibilities of 65 strains of
Streptococcus pneumoniae for which penicillin MICs covered
a broad range were assessed. The order of potency was amoxicillin (AMX) = amoxicillin-clavulanate (AMC) > penicillin G > cefpodoxime (CPO) > cefuroxime (CXM) > cefprozil > cefaclor > loracarbef > cefixime. No decrease in
susceptibility was seen following repeated subculture of two
penicillin-susceptible strains of S. pneumoniae in AMX, AMC, cefaclor, or loracarbef, whereas repeated exposure to CPO and CXM resulted in 4- to 32-fold decreases in susceptibility for both strains. When one of these strains
was exposed to concentrations of CPO, CXM, AMX, and AMC achieved
in the serum of humans following the administration of an oral dose,
all agents were rapidly bactericidal, with no decrease in
susceptibility up to 72 h. This was consistent with
antibiotic concentrations exceeding the MICs for 100% of the
dosing interval. For a penicillin-resistant strain, MICs were exceeded
for 29% of the 12-h dosing interval for 500 mg of AMX, 42% of the
interval for AMC with 875 mg of AMX and 125 mg of
clavulanate (875/125 mg of AMC) 21% of the interval for
500 mg of CXM, and 0% of the interval for 200 mg of CPO. Consequently,
only 875/125 mg of AMC produced a sustained bactericidal effect. A
four- to eightfold reduction in susceptibility to CPO and CXM and
cross-resistance with cefotaxime, but not penicillin or AMC, were
selected following exposure to simulated serum CPO and CXM
concentrations. In addition, AMX and AMC were the only agents which
consistently produced a >99% reduction in bacterial numbers in
time-kill studies using concentrations of antibiotic achieved in middle
ear fluid for all three strains of penicillin-resistant S. pneumoniae tested.
*
Corresponding author. Mailing address: c/o Tony White,
Anti-infectives SPD, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park (South), Third Avenue, Harlow, Essex CM19 5AW, United Kingdom. Phone: 01279 644373. Fax: 01279 646039.
Antimicrobial Agents and Chemotherapy, August 1998, p. 1973-1979, Vol. 42, No. 8
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»